Moderna and Mitsubishi Tanabe Partner to Promote mRNA Vaccines in Japan
Moderna, Inc. and Mitsubishi Tanabe Pharma Corporation announced a joint agreement for the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including its...
Moderna's novel mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products...
Geographic Atrophy Treatments Face Setbacks as EU Drug Regulator Rejects Apellis’ Syfovre Again
For the second time in six months, the European Medicines Agency's (EMA) European Committee for Medicinal Products for Human Use (CHMP) has rejected Apellis’...
Respiratory Syncytial Virus Vaccine mResvia Gains FDA Approval, Bolstering Moderna’s Market Position
Respiratory syncytial virus (RSV) vaccine mResvia (formerly mRNA-1345) has secured FDA approval, marking a significant milestone for Moderna as it seeks to diversify its...
FDA Delays Moderna’s Respiratory Syncytial Virus Vaccine Approval; Company Aims for Quick Resolution
Moderna, renowned for its groundbreaking contributions to combatting the COVID-19 pandemic with its innovative vaccines, embarked on a new frontier by venturing into the...
Artificial Intelligence Elevates Moderna’s Pioneering mRNA Medicine Development
Moderna has been a pioneer at the intersection of science, technology, and health, embracing machine learning and artificial intelligence (AI) since its inception to...
MAT -
Eli Lilly, Novo Nordisk, Moderna, and Regeneron achieved robust quarterly earnings, attributing it to the success of their drug and pipeline development initiatives. Eli...
MAT -
An agreement has been reached where Moderna will use Caris Life Sciences' library of de-identified, multi-modal health data solutions. These solutions have been generated...
